Capital Investment Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital Investment Advisory Services’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$849K	Sell	1,710 -1,073	-39%	-$476K	0.05%	334
2026 Q1	$1.24M	Sell	2,783 -179	-6%	-$83.5K	0.09%	227
2025 Q4	$1.34M	Sell	2,962 -186	-6%	-$80.2K	0.09%	206
2025 Q3	$1.23M	Sell	3,148 -632	-17%	-$264K	0.1%	216
2025 Q2	$1.68M	Sell	3,780 -198	-5%	-$91.2K	0.14%	161
2025 Q1	$1.93M	Sell	3,978 -212	-5%	-$98.8K	0.17%	137
2024 Q4	$1.69M	Sell	4,190 -450	-10%	-$209K	0.16%	139
2024 Q3	$2.16M	Sell	4,640 -1,137	-20%	-$546K	0.2%	116
2024 Q2	$2.71M	Sell	5,777 -85	-1%	-$36.9K	0.28%	82
2024 Q1	$2.45M	Sell	5,862 -50	-0.8%	-$21.1K	0.26%	88
2023 Q4	$2.41M	Buy	5,912 +119	+2%	+$44K	0.22%	82
2023 Q3	$2.01M	Buy	5,793 +144	+3%	+$50.4K	0.2%	92
2023 Q2	$1.99M	Hold	5,649	–	–	0.2%	88
2023 Q1	$1.78M	Buy	5,649 +6	+0.1%	+$1.8K	0.21%	92
2022 Q4	$1.63M	Sell	5,643 -33	-0.6%	-$10.1K	0.19%	99
2022 Q3	$1.64M	Sell	5,676 -55	-1%	-$15.8K	0.21%	89
2022 Q2	$1.61M	Sell	5,731 -305	-5%	-$81.6K	0.2%	99
2022 Q1	$1.57M	Sell	6,036 -7	-0.1%	-$1.66K	0.17%	120
2021 Q4	$1.33M	Sell	6,043 -420	-6%	-$81.7K	0.16%	136
2021 Q3	$1.17M	Buy	6,463 +300	+5%	+$58.6K	0.15%	137
2021 Q2	$1.24M	Sell	6,163 -160	-3%	-$33.5K	0.16%	129
2021 Q1	$1.36M	Buy	6,323 +100	+2%	+$22K	0.19%	115
2020 Q4	$1.47M	Buy	6,223 +3,160	+103%	+$725K	0.22%	100
2020 Q3	$834K	Sell	3,063 -817	-21%	-$225K	0.16%	135
2020 Q2	$1.13M	Sell	3,880 -75	-2%	-$20.3K	0.23%	96
2020 Q1	$941K	Buy	3,955 +80	+2%	+$18.4K	0.23%	92
2019 Q4	$848K	Buy	3,875 +437	+13%	+$88.4K	0.23%	96
2019 Q3	$582K	Sell	3,438 -50	-1%	-$8.85K	0.16%	121
2019 Q2	$607K	Sell	3,488 -1,107	-24%	-$194K	0.18%	116
2019 Q1	$845K	Sell	4,595 -626	-12%	-$116K	0.31%	58
2018 Q4	$865K	Sell	5,221 -114	-2%	-$19.8K	0.37%	54
2018 Q3	$1.03M	Sell	5,335 -5	-0.1%	-$890	0.48%	50
2018 Q2	$908K	Hold	5,340	–	–	0.45%	54
2018 Q1	$870K	Sell	5,340 -225	-4%	-$36.8K	0.49%	46
2017 Q4	$834K	Sell	5,565 -23	-0.4%	-$3.41K	0.49%	44
2017 Q3	$850K	Sell	5,588 -675	-11%	-$102K	0.52%	42
2017 Q2	$807K	Sell	6,263 -200	-3%	-$24.1K	0.53%	46
2017 Q1	$707K	Buy	6,463 +25	+0.4%	+$2.2K	0.52%	55
2016 Q4	$474K	Buy	+6,438	New	+$524K	0.41%	63

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Capital Investment Advisory Services's VRTX Position: Q2 2026 in Review

Capital Investment Advisory Services reduced its Vertex Pharmaceuticals (VRTX) stake by 39% in Q2 2026, selling an estimated $476K and leaving 1,710 shares worth $849K. The position accounts for 0.05% of the portfolio, ranked #334.

Capital Investment Advisory Services first reported a position in VRTX in Q4 2016 and has held it in 39 quarters since. The position peaked at $2.71M in Q2 2024. 484 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Capital Investment Advisory Services held 1,710 shares of Vertex Pharmaceuticals worth $849K as of Q2 2026.
Capital Investment Advisory Services sold 1,073 Vertex Pharmaceuticals shares in Q2 2026, an estimated $476K.
Vertex Pharmaceuticals made up 0.05% of Capital Investment Advisory Services's portfolio in Q2 2026, its #334 holding.
Capital Investment Advisory Services first reported a position in Vertex Pharmaceuticals in Q4 2016 and has held it in 39 quarters since.
Capital Investment Advisory Services's Vertex Pharmaceuticals position peaked at $2.71M in Q2 2024.
484 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Capital Investment Advisory Services's 13F filing for Q2 2026, filed 23 Jul 2026.